Concepedia

Tom Le Voyer

TL

24

Publications

2.4K

Citations

22

H-Index

2020

Active since

Affiliations

Inserm(Current)

Rockefeller University

Université Paris Cité

Institut des Maladies Génétiques Imagine

Assistance Publique – Hôpitaux de Paris

Tom Le Voyer is an author at Inserm specializing in immunology, medicine, and autoimmune disease.

ORCID

Top concepts

Publications per year

2020–2024

24

Publications

24

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Paul Bastard, Adrian Gervais, Tom Le Voyer et al. · Science Immunology · 2021 · 600 citations · Full text

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Paul Bastard, Elizaveta Orlova, Leila Sozaeva et al. · The Journal of Experimental Medicine · 2021 · 295 citations · Full text

, , +14

Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine

Paul Bastard, Eleftherios Michailidis, Hans-Heinrich Hoffmann et al. · The Journal of Experimental Medicine · 2021 · 224 citations · Full text

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

Jérémy Manry, Paul Bastard, Adrian Gervais et al. · Proceedings of the National Academy of Sciences · 2022 · 180 citations · Full text

, , +16

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

Qian Zhang, Andrés Pizzorno, Lisa Miorin et al. · The Journal of Experimental Medicine · 2022 · 112 citations · Full text

Rows per page

1–5 of 24